A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

INTRODUCTION: To assess the efficacy and the Src-kinase inhibitor saracatinib (AZD-0530) after 4 cycles of platinum-based chemotherapy for extensive stage small cell lung cancer (SCLC). METHODS: Patients with at least stable disease received saracatinib at a dose of 175 mg/day by mouth until disease...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer
Main Authors: Molina, Julian R., Foster, Nathan R., Reungwetwattana, Thanyanan, Nelson, Garth D., Grainger, Andrew V., Steen, Preston D., Stella, Philip J., Marks, Randolph, Wright, John, Adjei, Alex A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652328/
https://ncbi.nlm.nih.gov/pubmed/24957683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2014.03.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados